



49TH

Annual conference of Mumbai Hematology Group (MHG) & Essence of ASH - Dec 2025

with international guest speakers



**Saturday-Monday
24th to 26th of January 2026**

Venue:

S. P. Jain Auditorium, 4th floor, New Wing,
Bombay Hospital Institute of Medical Sciences,
Marine Lines, Mumbai, India

May Fair Hall, Ground Floor, Hotel West End,
Opp. Bombay Hospital, Marine Lines,
Mumbai, India



49TH

Annual conference of Mumbai Hematology Group (MHG) & Essence of ASH - Dec 2025
Saturday-Monday, 24th to 26th of January 2026 🍷 (With international guest speakers)

Executive committee

Mumbai Hematology Group

President

Dr. M. B. Agarwal

Vice-President

Dr. S D Banavali

Secretary

Dr. Rucha Patil

Treasurer

Dr. Subhaprakash Sanyal

Members

Dr. Shubhangi Agale

Dr. Roshan Colah

Dr. Dipanjan Haldar

Dr. S Khodaiji

Dr. Vrinda Kulkarni

Dr. Navin Khattry

Dr. Chandrakala S

Dr. Asha Shah

Dr. Shrimati Shetty

Dr. Bipin Kulkarni



49TH

Annual conference of Mumbai Hematology Group (MHG) & Essence of ASH - Dec 2025
Saturday-Monday, 24th to 26th of January 2026  (With international guest speakers)

Faculty

International

Dr. Charles Craddock, UK

Dr. LIM Zi Yi, Singapore

Dr. Matthew Matasar, USA

Dr. Meera Mohan, USA

Dr. Niranjan N Rathod, New Zealand

Dr. Nitin Jain, USA

National

This is under planning

Local (Mumbai)

This is under planning



49TH

Annual conference of Mumbai Hematology Group (MHG) & Essence of ASH - Dec 2025
Saturday-Monday, 24th to 26th of January 2026 (With international guest speakers)



Mumbai Hematology Group

Dear Colleagues & Students,

We extend a cordial invitation to you for the 49th Annual conference of Mumbai Hematology Group (MHG) & Essence of ASH-Dec 2025 which is an in-person (physical) meeting (not hybrid).

This is organized by Mumbai Hematology Group (MHG).

There will be eminent international experts in both classical and malignant hematology covering various advances of practical importance.

Besides, we will have a galaxy of Indian faculty (both national and from Mumbai).

We are sure that once again, you will register in large numbers and benefit from this academic event. Also, this is an opportunity to meet our colleagues and friends and also develop new acquaintances.

We look forward to a very vibrant educational event.

Your sincerely,



Dr. Rucha K. Patil
Secretary
Mumbai Hematology Group



Dr. M.B. Agarwal
President
Mumbai Hematology Group

International faculty



Prof. Charles Craddock, Birmingham



Dr. LIM Zi Yi, Singapore



Dr. Matthew Matasar, USA



Dr. Meera Mohan, USA



Dr. Niranjan N Rathod, New Zealand



Dr. Nitin Jain, USA

International faculty



Prof. Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci
Professor of Haemato-oncology
University of Warwick
Academic Director Centre for Clinical Haematology
University Hospitals Birmingham
UK

- Dr. Charles Craddock is Professor of Haemato-oncology at the University of Warwick and Academic Director of the Centre for Clinical Haematology at University Hospitals Birmingham.
- He is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014.
- He is a past President of the British Society of Haematology.
- He pioneered the development of both the UK Haemato-oncology Trials Acceleration Programme and stem cell transplant trials network, IMPACT.
- In 2021, he founded Accelerating Clinical Trials Ltd, an innovative haemato-oncology trials delivery vehicle.
- He has published more than 275 papers in peer reviewed journals.
- He was awarded the CBE for services to medicine in the 2016 New Year's Honours list and elected a Fellow of the Academy of Medical Sciences in 2020.

International faculty



Dr Lim Zi Yi, M.D., Ph.D.

Senior Consultant Haematologist & Medical Director
Mount Elizabeth Novena Specialist Centre
Singapore

- Dr Lim Zi Yi is the Medical Director of CFCH and a Senior Consultant in Haematology.
- He has more than two decades of experience as a haematologist having worked at top haematology centres in both London and Singapore.
- He has a specialist interest in Haemato-oncology and Haematopoietic Stem Cell Transplantation.
- He is experienced in the treating of patients with haematological diseases including acute leukaemia, myelodysplastic syndromes, lymphoma, myeloma and aplastic anaemia.
- In addition, he has wide experience in the management of general haematological conditions (such as clotting disorders, anaemia, bleeding disorders).
- He received his medical degree from the University of Edinburgh, UK and subsequently underwent specialist training in haemato-oncology at Kings College Hospital, London.
- He did research as a Clinical Lecturer in Haematology at King College London for two years on transplant immunology before returning to full time clinical work. During his tenure at King College Hospital, he helped to develop it into one of the largest allogeneic haematopoietic stem cell transplant centres in Europe. During his time in London, he published more than 40 papers and presented more than 100 abstracts at international conferences.
- In 2007, he was awarded the prestigious Tito Bastianello Award for Best Young Investigator, at the 9th International Symposium on Myelodysplastic Syndromes, in Italy.
- He has also been the principal author on several key highly cited papers in the field of myelodysplastic syndromes and allogeneic hematopoietic stem cell transplantation.
- He returned to Singapore in 2011 where he has led the development of several haematological services in the public and private sector.
- He was awarded the NUHS Clinician Scientist Program Award in 2012.
- He is presently the Medical Director of the Centre for Clinical Haematology, as well as a Visiting Consultant at the National University Cancer Institute, Singapore.
- He continues to be active in medical research and clinical trials and is passionate about the development of new treatment strategies for patients with complex haematological disorders.

International faculty

- He is presently working on introducing new innovative therapies such as CAR-T cell therapies and other cellular therapies into Singapore.
- He has been the President of the Singapore Bone Marrow Programme since 2013.
- The Charity runs the bone marrow registry for Singapore, and Dr Lim has been passionate about raising awareness of blood disorders and working to increase funding and support for patients and relatives affected by the disorder.
- He also serves on several committees advising blood cancers, including the MOH Bone Marrow/Hematopoietic Stem Cell Transplant Working Committee, the MOH COVID-19 Transplantation Services Advisory Committee as well as the MOH Drug Advisory Committee.
- He is also part of the Medical Advisory Board and Chair of the Blood Transfusion Services Committee for both Mount Elizabeth Novena Hospital and Mount Alvernia Hospital.
- He believes in approaching patient care in a holistic manner.
- He works closely with patients and their families to map out treatment options, and his CFCH team will work to support patients through all phases of their haematology journey.
- He is fluent in English and Chinese.

Qualifications

- MBChB, University of Edinburgh
- Fellow of the Royal College of Pathologists, UK
- Fellow of the Royal College of Physicians (Edinburgh), UK
- Tito Bastianello Award for Best Young Investigator, 9th International Symposium on Myelodysplastic Syndromes, Italy, 2007
- Awarded the NUHS Clinician Scientist Program Award, 2012

Background

- He worked at King's College Hospital, London for almost 10 years
- Experienced in various forms of allogeneic haematopoietic stem cell transplantation and has personally overseen the management of more than 350 bone marrow transplants since 2008
- Published more than 50 peer-reviewed papers on myeloid cancers and transplantation, many in high-impact journals such as Journal of Clinical Oncology, Blood, Leukemia and Haematologica
- Lead for adult leukaemia service at NUHS (2011-2013)
- Lead for adult haematopoietic stem cell transplant service at Parkway Cancer Centre (2013-2019)
- President of the Bone Marrow Donor Programme (BMDP) Singapore
- Co-Founder and CEO of the cellular therapy manufacturing start-up CellVec Pte Ltd
- Formed the Centre for Clinical Haematology 2019

International faculty



Dr. Matthew Matasar

Chief, Division of Blood disorders
Rutgers Cancer Institute
New Jersey, USA

- Dr. Matthew Matasar graduated from Harvard College and Harvard Medical School. He moved to New York to train in medicine at Columbia-Presbyterian Medical Center.
- After completing training in internal medicine, He served as a Chief Resident at Columbia-Presbyterian Medical Center and while completing a master's degree at the Mailman School of Public Health, he joined Memorial Sloan Kettering Cancer Center to pursue advanced training in cancer medicine and has been dedicated to caring for patients with lymphoma ever since.
- His research is focused on finding new and better ways to treat lymphoma, particularly high-risk aggressive lymphomas, and certain uncommon types of non-Hodgkin lymphoma.
- He is an internationally recognized leader in the oncology field where he served as member of the board of the New Jersey chapter of the Leukemia and Lymphoma Society, member of the American Society of Hematology's national Committee on Quality and others.
- In 2022, He joined the Rutgers Cancer Institute of New Jersey and RWJBarnabas Health.
- He joins a team of professionals deeply committed to the art and science of caring for people facing a diagnosis of cancer.
- He is committed to ensuring his patients receive the best treatments delivered in the best ways, and to being a partner and advocate to guide them through what can be a very difficult time.

International faculty



Dr. Meera Mohan

Assistant Professor
Division of Hematology/Oncology
Department of Medicine
Medical College of Wisconsin
Milwaukee, Wisconsin, USA

- Dr. Meera Mohan holds the position of Assistant Professor within the Division of Hematology Oncology, specializing in Bone Marrow Transplantation and Cellular Therapy at the Medical College of Wisconsin.
- Her educational journey commenced at the Kerala Medical University in India, where she completed her medical school training.
- Subsequently, she pursued her residency at Wayne State University, followed by a clinical fellowship at the University of Arkansas, where she also served as Chief Fellow.
- Currently, her clinical and research focus is plasma cell dyscrasia.
- She serves as the principal investigator of several clinical trials in patients with multiple myeloma.
- She has co-authored and authored close to 100 peer reviewed publication in her short career thus far and is the recipient of KL2 career development award for her work on minimal residual disease in myeloma.

International faculty



Dr. Niranjan Rathod, MBBS, MD, DM, FRACP, FACP
Consultant Haematologist & Lead Transplant Physician
Health New Zealand, Waikato
Honorary Senior Lecturer
University of Auckland,
Hamilton New Zealand

- Dr. Rathod currently leads the Transplant Program and chairs the Myeloma Disease Group at the Regional Cancer Centre, Waikato Hospital, New Zealand. He is a trained haematologist with subspecialty expertise in cellular therapy and stem cell transplantation, having completed advanced training at Fred Hutchinson Cancer Research Center, Seattle, and AIIMS, New Delhi. He has over 15 years of experience in malignant haematology and stem cell transplantation within teaching and tertiary care institutions.
- Dr. Rathod recently completed a sabbatical in Transplant and Cellular Therapy (TCT) at Fred Hutch, Seattle, further strengthening his expertise in TCT (CAR-T, TCR, TIL, TCE, BiTe, GVHD, LTFU) and patient care models.
- He has been instrumental in establishing multiple allogeneic stem cell transplant programs across Mumbai, including the landmark achievement of leading the first successful bone marrow transplant (BMT) in a public hospital (LTMGH) in Mumbai and in the state of Maharashtra. At Waikato, he has systematically developed chronic GVHD and long-term follow-up (LTFU) services, addressing key post-transplant care needs across the region.
- An accomplished educator, Dr. Rathod has over 11 years of university-level teaching experience at both Mumbai University and the University of Auckland. He is an accredited supervisor with the Royal Australasian College of Physicians (RACP) for both basic and advanced haematology training, and actively mentors' trainees. His commitment to medical education extends to ongoing contributions to educational activities with the RACP and the American College of Physicians. He also serves as a peer reviewer for indexed journals including the Internal Medicine Journal (IMJ) of RACP and the Indian Journal of Haematology and Blood Transfusion (IJHBT).

International faculty

- As a clinical researcher, he has led numerous local and national research projects and served as Principal Investigator (PI) for several multinational clinical trials, such as the ENHANCE Phase 3 trial, AML MRC, ALLG ABCR, MM-5, MM-6, and others. He currently leads the Haematology Department's research efforts and is the national PI for the upcoming MagnetisMM-6 trial in myeloma T-cell engager (TCE) therapies.
- Dr. Rathod is an active member of the Australasian Leukaemia & Lymphoma Group (ALLG), representing New Zealand in the AML/MDS Scientific Working Party, and serves on the ALLG Medical Advisory Committee (MAC) as part of the patient advocacy group.

His clinical and research interests include:

- Cellular therapy (including CAR-T) in lymphoma and myeloma
- Chronic graft-versus-host disease (GVHD) & Long-term follow-up (LTFU) post-transplant
- Targeted therapies in myeloid malignancies such as AML, MDS, and myelofibrosis (MF)

International faculty



Dr. Nitin Jain

Professor

Dept of Leukemia

The University of Texas

MD Anderson Cancer Center

Houston, Texas, USA

- He is Professor, Dept of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
- He earned his medical degree from AIIMS, Delhi in 2002.
- He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee, Wisconsin.
- He then completed Clinical Fellowship in Leukemia at MD Anderson Cancer Center followed by Leukemia Research Fellowship at Memorial Sloan-Kettering Cancer Center in NY.
- He then pursued fellowship in Hematology/Oncology at the University of Chicago.
- He joined as a faculty member in the Department of Leukemia at MD Anderson Cancer Center in 2012.
- He treats patients with acute and chronic leukemia with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
- His research interests focus on new drug development for patients with leukemia, especially CLL and ALL.

Lectures by international faculty



Dr. Charles Craddock, Birmingham

- a. Emerging new options in the Management of AML
- b. Stem Cell Transplant in AML: Who, When and How?
- c. Strategies to Improve Outcome in Adults Transplanted with AML
- d. Case discussion session



Dr. LIM Zi Yi, Singapore

- a. Clonal Haematopoiesis: Implications for Cardiovascular Disease, Haematological Malignancies and Inflammation
- b. Haplo-identical & Mismatched Allo-HSCT
- c. Role of Asian National Bone Marrow Registries: Lessons from the Singapore Bone Marrow Donor Programme
- d. Case discussion session



Dr. Matthew Matasar, USA

- a. Advances in the management of newly diagnosed diffuse large B-cell lymphoma
- b. Updates in the management of follicular lymphoma
- c. Relapsed/refractory DLBCL: evolving standards of care
- d. Case discussion session



Dr. Meera Mohan, USA

- a. Bispecific antibody therapy in multiple myeloma.
- b. Practical aspects of CAR-T therapy in myeloma.
- c. All about MRD in myeloma
- d. High-risk myeloma
- e. Case discussion session



Dr. Niranjana N Rathod, New Zealand

- a. High risk MDS management update
- b. Myelofibrosis treatment update
- c. Updates in chronic GVHD
- d. Case discussion session



Dr. Nitin Jain, USA

- a. Frontline Therapy of CLL in 2026
- b. What's New in Management of Relapsed CLL?
- c. Evolving Role of CAR T in Adult ALL
- d. Case discussion session



49TH

Annual conference of Mumbai Hematology Group (MHG) & Essence of ASH - Dec 2025
Saturday-Monday, 24th to 26th of January 2026 (With international guest speakers)

Paper presentation (Dr. J. C. Best paper award session, Oral or Poster presentation)

Instructions for submitting papers for oral or poster or Dr. J. C. Patel best paper award Session (to send the email to mbagarwal1@gmail.com)

- Following details are required before **1st November 2025 (5 pm)**.

This information has to be final and cannot be modified later.

In general, case reports will not be accepted unless they have extraordinary work-up and an impact factor.

Please indicate whether paper is for oral or poster or Dr. J. C. Patel best paper award presentation
(please tick one):

1. ☐ Oral presentation 2. ☐ Poster presentation 3. ☐ Dr. J. C. Patel best paper award

- Title of the paper:

- Name of first author:

Dr / Mr / Ms _____
(surname) (first name) (middle name)

(Presenting author must be the first author. Paper can be from Mumbai or any other part of India)

- Names of other authors in order:

- Designation of the first author:

- Affiliations of the first author:

- Details of the department and institutions of the co-authors:

- Email ID of the presenting author: _____

- Mobile number of the presenting author: _____

- Abstract of the paper can be submitted upto 30th November 2025 (5 pm).

- A sample copy of the abstract is attached.

Sample abstract

Please select one : This paper is for Oral / Poster / Dr. J. C. Patel best paper award session

First Report of Molecular Characterization of Congenital Dyserythropoietic Anaemia Type I with a CDAN1 gene mutation diagnosed by Next Generation Sequencing panel

Presenting author: Arati Nandan Saptarshi

Co-authors: Rashmi Dongerdiye, Tejashree Anil More, Dr. Prabhakar S. Kedar

ICMR-National Institute of Immunohaematology, 13th floor, New Multistoried Building,
KEM Hospital, Parel, Mumbai 400012

Abstract:

Background: Congenital dyserythropoietic anaemias (CDAs) are a rare, heterogeneous group of disorders characterized by ineffective erythropoiesis. CDAI is very rare and caused due to mutations in the CDAN1 or c15orf41 gene. There is no report on the molecular characterization of CDA I in the Indian population. An 8-year-old transfusion-dependent patient was referred for haemolytic anaemia workup. Common causes of congenital haemolytic anaemia were ruled out. A bone marrow aspiration study showed erythroid hyperplasia with mild dyserythropoiesis. Thus, the patient was considered for molecular characterization using next-generation sequencing.

Objective:

Diagnosis of unexplained congenital anaemia using next-generation sequencing.

Method:

Next-generation sequencing panel was used for identification of the disease-causing variant; bioinformatics tools were used to predict pathogenicity of the variant and functional validation was performed by gene expression studies using quantitative real-time PCR.

Results:

Red cell membrane, enzyme, hemoglobinopathy, and autoimmune hemolytic anaemia studies were normal. Bone marrow aspiration study showed erythroid hyperplasia with mild dyserythropoiesis. The patient showed c. 2671C>T, p. Arg891Cys variant in the CDAN1 gene using next-generation sequencing. Bioinformatics tools like SIFT, PolyPhen 2.0 predicted the variant to be damaging and deleterious. The expressions of CDAN1 and c15orf41 genes studied using quantitative real-time PCR were significantly reduced as compared to healthy controls.

Conclusion:

Next-generation sequencing confirmed the diagnosis of CDA I in a patient who underwent excessive investigation earlier. CDA, being clinically similar to other prevalent causes of anaemia, should be kept in mind especially when the common causes have already been ruled out. Further, the use of in-silico tools and gene expression analysis validated the functional impact of this variant.

Correspondence:

Arati Nandan Saptarshi, PhD Student, ICMR - National Institute of Immunohaematology,
13th floor, NMS Building, KEM Hospital Campus, Parel, Mumbai - 400012

Email ID: arati611@gmail.com

Cell: 8550903330



49TH

Annual conference of Mumbai Hematology Group (MHG) & Essence of ASH - Dec 2025
Saturday-Monday, 24th to 26th of January 2026  (With international guest speakers)

Venue:

S. P. Jain Auditorium, 4th floor, New Wing,
Bombay Hospital Institute of Medical Sciences, Marine Lines, Mumbai, India
May Fair Hall, Ground Floor, Hotel West End,
Opp. Bombay Hospital, Marine Lines, Mumbai, India

Registration details



Category	Up to 31st Oct 2025	Up to 30th Nov 2025	Up to 31st Dec 2025	From 1st January 2026 including Spot registration
MHG members *	₹1000 /-	₹ 2000 /-	₹ 3000 /-	₹ 4000 /-
Students **	₹ 1000 /-	₹ 2000 /-	₹ 3000 /-	₹ 4000 /-
Delegates	₹ 2000 /-	₹ 3000 /-	₹ 5000 /-	₹ 7000 /-
Trade registration	₹ 4000 /-	₹ 6000 /-	₹ 8000 /-	₹ 10,000 /-
International Delegate	US \$ 100	US \$ 150	US \$ 200	US \$ 250

Note: * Membership number must be forwarded.

** Proof to be submitted

Registration fee is non-refundable

Click on below link to register:

<http://eventshub.trackbite.in/UserForm?x=mhg2026>



Under the aegis of

Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road, Dadar TT,
Mumbai 400014.

Email ID: mbagarwal1@gmail.com

Website: www.mhgindia.com